Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is a leading pure-play in mRNA capping and viral clearance assessment and while the current valuation likely limits downside, the firm’s Neutral view is based on its call that there are “more attractive categories within the bioprocessing subsegment.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences chairman Carl Hull to retire, R. Andrew Eckert to succeed
- Maravai LifeSciences Appoints New Chairman Amid Leadership Transition
- Maravai Lifesciences downgraded to Sell from Neutral at Goldman Sachs
- Maravai Lifesciences initiated with a Peer Perform at Wolfe Research
- Maravai Lifesciences price target lowered to $7 from $10 at Morgan Stanley